Company: CERO
Filing Date: 2025-07-14
Form Type: 424B3
Source: 0001213900-25-063764
Chunk: 3

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-07-14
Form: 424B3
Chunk 3
---
 As a result, Nasdaq canceled the hearing and the Common Stock
will continue to be listed and traded on the Nasdaq Capital Market.

<div align='center'>SIGNATURE</div>

Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.

| Dated: July 8, 2025 | CERO THERAPEUTICS HOLDINGS, INC. |                         |
|:--------------------|:---------------------------------|:------------------------|
|                     | By:                              | /s/ Chris Ehrlich       |
|                     | Name:                            | Chris Ehrlich           |
|                     | Title:                           | Chief Executive Officer |

<div align='center'>UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or Section 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 11, 2025

CERO THERAPEUTICS HOLDINGS, INC.

(Exact name of registrant as specified in its charter)</div>

| Delaware                        |     | 001-40877               |     | 87-1088814            |
| (State or other jurisdiction of 
 incorporation or organization)  |     | -Commission File Number |     | -I.R.S. Employer      
 Identification Number |

| 201 Haskins Way, Suite 230, South San Francisco, CA |     |     94080 |
| (Address of principal executive offices)            |     | -Zip Code |

<div align='center'>(650) 407-2376

Registrant’s telephone number, including area code

Not applicable

(Former name or former address, if changed since last report)</div>

Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)                  |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)                 |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act